BRPI0815154A2 - Compostos de indol, composição para a prevenção ou tratamento de necrose e doenças associadas com a necrose, e, método de preparação da mesma - Google Patents

Compostos de indol, composição para a prevenção ou tratamento de necrose e doenças associadas com a necrose, e, método de preparação da mesma

Info

Publication number: BRPI0815154A2
Authority: BR; Brazil
Prior art keywords: necrosis; prevention; preparation; treatment; composition
Prior art date: 2007-08-17

Application number

Other languages

English (en)

Inventor

Soon Ha Kim

Hyoung Jin Kim

Sun Young Koo

Sung Bae Lee

Heui Sul Park

Seung Hyun Yoon

Seung Yup Paek

Hyo Shin Kwak

Dong Ook Seo

Eok Park

Original Assignee

Lg Life Sciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-17

Filing date

2008-08-18

Publication date

2015-03-31

2008-08-18 Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd

2015-03-31 Publication of BRPI0815154A2 publication Critical patent/BRPI0815154A2/pt

2024-01-30 Publication of BRPI0815154B1 publication Critical patent/BRPI0815154B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Immunology (AREA)
Oncology (AREA)
Hematology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Obesity (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)

BRPI0815154-7A 2007-08-17 2008-08-18 Compostos de indol, composição, e, método de preparação da mesma BRPI0815154B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR20070082687		2007-08-17
KR10-2007-0082687		2007-08-17
PCT/KR2008/004783 WO2009025477A1 (en)	2007-08-17	2008-08-18	Indole compounds as an inhibitor of cellular necrosis

Publications (2)

Publication Number	Publication Date
BRPI0815154A2 true BRPI0815154A2 (pt)	2015-03-31
BRPI0815154B1 BRPI0815154B1 (pt)	2024-01-30

Family

ID=40378334

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0814958A BRPI0814958B8 (pt)	2007-08-17	2008-08-18	compostos de indol, e, composição
BRPI0815154-7A BRPI0815154B1 (pt)	2007-08-17	2008-08-18	Compostos de indol, composição, e, método de preparação da mesma

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BRPI0814958A BRPI0814958B8 (pt)	2007-08-17	2008-08-18	compostos de indol, e, composição

Country Status (13)

Country	Link
US (5)	US8222414B2 (pt)
EP (2)	EP2178870B1 (pt)
JP (2)	JP5517935B2 (pt)
KR (2)	KR20090018593A (pt)
CN (2)	CN101784543B (pt)
BR (2)	BRPI0814958B8 (pt)
DK (1)	DK2178870T3 (pt)
ES (2)	ES2691068T3 (pt)
MX (1)	MX368368B (pt)
PT (1)	PT2178870T (pt)
RU (2)	RU2477282C2 (pt)
SI (1)	SI2178870T1 (pt)
WO (2)	WO2009025478A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2178870T1 (sl) *	2007-08-17	2018-11-30	Lg Chem, Ltd.	Indolne in indazolne spojine kot inhibitor celične nekroze
US20090142832A1 (en)	2007-11-29	2009-06-04	James Dalton	Indoles, Derivatives, and Analogs Thereof and Uses Therefor
EP2220081A4 (en) *	2007-12-20	2011-08-24	Lg Life Sciences Ltd	GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES
RU2460525C2 (ru) *	2008-01-04	2012-09-10	Эл Джи Лайф Сайенсиз Лтд.	Производные индола и индазола, обладающие консервирующим действием по отношению к клеткам, тканям и органам
MX2010011138A (es) *	2008-04-10	2010-11-12	Takeda Pharmaceutical	Compuestos de anillo fusionados y uso de los mismos.
JPWO2010076884A1 (ja)	2008-12-29	2012-06-21	武田薬品工業株式会社	新規縮合環化合物およびその用途
TWI535440B (zh) *	2009-10-26	2016-06-01	Ｌｇ生命科學有限公司	包括吲哚化合物之醫藥組成物
KR101304772B1 (ko) *	2011-04-11	2013-09-05	인제대학교 산학협력단	ＮｅｃｒｏＸ―５를 유효성분으로 포함하는 미토콘드리아 기능 조절용 조성물
CN102766083B (zh) *	2011-05-03	2014-10-22	中国科学院上海有机化学研究所	2-氨基-3-全氟乙酰吲哚类化合物及其衍生物、制备方法和应用
KR101404151B1 (ko) *	2011-11-25	2014-06-05	가톨릭대학교 산학협력단	안과 질환의 예방 및 치료용 약학 조성물
KR101941004B1 (ko) *	2013-03-25	2019-01-23	주식회사 엘지화학	조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
KR102139339B1 (ko) *	2013-06-24	2020-07-29	주식회사 엘지생활건강	인돌 화합물을 포함하는 용해도가 개선된 화장료 조성물
KR102139338B1 (ko) *	2013-06-24	2020-07-29	주식회사 엘지생활건강	인돌 화합물을 포함하는 용해도가 개선된 화장료 조성물
KR101985886B1 (ko) *	2013-06-24	2019-06-04	주식회사 엘지생활건강	인돌 화합물 및 판테놀을 포함하는 자외선에 의한 피부손상 예방 및 개선용 조성물
CN105636956B (zh) *	2013-08-22	2019-07-09	株式会社Lg化学	作为细胞坏死阻碍剂的吲哚化合物
CN105658625B (zh) *	2013-08-22	2019-05-03	株式会社Lg化学	作为细胞坏死阻碍剂的吲哚酰胺化合物
CN103601662B (zh) *	2013-11-21	2016-04-06	深圳市药品检验所	一种褪黑素半抗原、褪黑素完全抗原及其制备方法和应用
WO2015111947A1 (en) *	2014-01-24	2015-07-30	Lg Life Sciences Ltd.	Composition for preventing or treating acute lung injury and acute respiratory distress syndrome
ES2851006T3 (es) *	2014-04-18	2021-09-02	Lg Chemical Ltd	Composición para prevenir o tratar esteatosis hepáticas
TW201707707A (zh) *	2015-03-26	2017-03-01	Ｌｇ生命科學股份有限公司	包含吲哚化合物之製劑及其製備方法
US10968185B2 (en) *	2015-04-07	2021-04-06	Ela Pharma Ltd.	Substituted thiazoles for preventing and/or treating cell or tissue necrosis
KR102446529B1 (ko) *	2017-01-10	2022-09-23	에테하 취리히	세포 보호 화합물 및 이의 용도
JOP20210131A1 (ar)	2018-12-17	2023-01-30	Vertex Pharma	مثبطات apol1 وطرق استخدامها
CN109884212A (zh) *	2019-03-27	2019-06-14	清华大学深圳研究生院	基于化学衍生化与hplc-ms的不饱和脂肪酸定量方法
CN114080382B (zh) *	2019-06-19	2024-05-24	株式会社Lg化学	制备吲哚或吲唑化合物的方法
KR102389717B1 (ko)	2019-06-19	2022-04-25	주식회사 엘지화학	인돌 또는 인다졸 화합물의 제조방법
KR102397752B1 (ko)	2019-06-19	2022-05-16	주식회사 엘지화학	인돌 또는 인다졸 화합물의 제조방법
US12358879B2 (en)	2019-10-18	2025-07-15	Takeda Pharmaceutical Company Limited	Heterocyclic compound
BR112022010561A2 (pt)	2019-12-02	2022-11-16	Storm Therapeutics Ltd	Compostos poli-heterocíclicos como inibidores de mettl3
EP4097083A1 (en)	2020-01-29	2022-12-07	Vertex Pharmaceuticals Incorporated	Inhibitors of apol1 and methods of using same
WO2021154902A1 (en) *	2020-01-30	2021-08-05	Anima Biotech Inc.	Collagen 1 translation inhibitors and methods of use thereof
EP4114385A1 (en)	2020-03-06	2023-01-11	Vertex Pharmaceuticals Incorporated	Methods of treating apol-1 dependent focal segmental glomerulosclerosis
WO2021201609A1 (ko)	2020-03-31	2021-10-07	주식회사 엘지화학	췌도 이식 보호용 조성물
EP4165023A1 (en) *	2020-06-12	2023-04-19	Vertex Pharmaceuticals Incorporated	Inhibitors of apol1 and use of the same
AU2021286728A1 (en)	2020-06-12	2023-01-19	Vertex Pharmaceuticals Incorporated	Inhibitors of APOL1 and use of the same
WO2022039506A1 (ko)	2020-08-19	2022-02-24	주식회사 미토이뮨테라퓨틱스	Ｍabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
IL318169A (en)	2020-08-26	2025-03-01	Vertex Pharma	Apol1 inhibitors and methods of use are the same
EP4382106A4 (en) *	2021-04-12	2025-04-02	MitoImmune Therapeutics Inc.	Composition for inhibiting inflammation or ageing of stem cells and method for inhibiting inflammation or ageing therewith
US20240199598A1 (en) *	2021-04-12	2024-06-20	Mitoimmune Therapeutics Inc.	Sulfate of 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-n-(tetrahydro-2h-pyran-4-yl)-1h-indole-7-amine, and novel crystal form thereof
EP4324830A4 (en) *	2021-04-12	2025-04-16	MitoImmune Therapeutics Inc.	NEW CRYSTAL FORM OF 5-[(1,1-DIOXIDO-4-THIOMORPHOLINYL)METHYL)-2-PHENYL-N-(TETRAHYDRO-2H-PYRAN-4-YL)-1H-INDOLE-7-AMINE
DE102021207925A1 (de) *	2021-07-23	2023-01-26	Continental Reifen Deutschland Gmbh	Verbindung, Verfahren zu deren Herstellung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Ozonschutzmittel und/oder Farbstoff
CA3227666A1 (en)	2021-08-02	2023-02-09	Soon Ha Kim	Novel indole derivatives, pharmaceutical compositions comprising the same, and use thereof
US20250289785A1 (en)	2021-08-02	2025-09-18	Mitoimmune Therapeutics Inc.	Indole derivative, method for preparing same, and use thereof
WO2023106973A1 (ru) *	2021-12-10	2023-06-15	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Новые гепатопротекторные средства
AU2023213494A1 (en)	2022-01-27	2024-08-08	Mitoimmune Therapeutics Inc.	Ovarian anti-aging pharmaceutical composition and use thereof
WO2023182840A1 (ko)	2022-03-25	2023-09-28	주식회사 미토이뮨테라퓨틱스	항바이러스용 약학적 조성물 및 이의 용도
WO2024158205A1 (ko) *	2023-01-25	2024-08-02	주식회사 미토이뮨테라퓨틱스	치환기를 가지는 인돌 유도체, 및 약학적 용도
KR20240118677A (ko)	2023-01-27	2024-08-05	주식회사 미토이뮨테라퓨틱스	페롭토시스 억제제로서 인돌 화합물의 용도
WO2024191106A1 (ko)	2023-03-13	2024-09-19	주식회사 미토이뮨테라퓨틱스	뇌전증 예방 또는 치료용 약학적 조성물
WO2025188159A1 (ko)	2024-03-06	2025-09-12	주식회사 미토이뮨테라퓨틱스	신장 섬유증 예방 또는 치료용 약학적 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB599834A (en) *	1943-04-08	1948-03-22	Francolor Sa	Improvements in or relating to the manufacture of azodyestuffs
US3755332A (en) *	1971-07-01	1973-08-28	Ciba Geigy Corp	Substituted 4 indazolaminoquinolines
BE792078A (fr) *	1971-12-01	1973-05-29	Wander Ag Dr A	Nouveaux derives de l'indazole, leur preparation et leur application comme medicaments
DE2653005A1 (de) *	1975-12-03	1977-06-08	Sandoz Ag	Neue organische verbindungen, ihre verwendung und herstellung
JPS6160648A (ja) *	1984-08-31	1986-03-28	Teikoku Hormone Mfg Co Ltd	２−（３，５−ジアルキル−４−ヒドロキシフエニル）インド−ル誘導体
US5254135A (en) *	1989-10-20	1993-10-19	L'oreal	Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use
FR2659552B2 (fr) *	1989-10-20	1994-11-04	Oreal	Procede de teinture des fibres keratiniques avec des aminoindoles, composition et dispositif de mise en óoeuvre.
AU8225991A (en) *	1990-07-31	1992-03-02	Teikoku Hormone Mfg. Co., Ltd.	2-phenylindole derivative
FI944602A7 (fi) *	1992-04-03	1994-10-03	Upjohn Co	Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit
EP0676967A4 (en)	1992-12-30	1996-10-02	Fmc Corp	RELEASED, EXTENDED, EASY TO PRODUCE EXCIPIENT, BASED ON KONJAC GLUCOMANNANE.
JP3545461B2 (ja) *	1993-09-10	2004-07-21	エーザイ株式会社	二環式ヘテロ環含有スルホンアミド誘導体
DK0673937T3 (da)	1993-09-10	2004-03-22	Eisai Co Ltd	Bicyclisk heterocyclisk sulfonamid og sulfonsyreesterderivater
KR20000057137A (ko)	1996-11-19	2000-09-15	스티븐 엠. 오드레	아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
FR2767475A1 (fr) *	1997-08-25	1999-02-26	Oreal	Compositions de teinture des fibres keratiniques contenant des derives d'indazoles et procede
US6858577B1 (en) *	1999-06-29	2005-02-22	Ortho-Mcneil Pharmaceutical, Inc.	Indole peptidomimetics as thrombin receptor antagonists
US6660744B1 (en) *	1999-09-17	2003-12-09	Abbott Gmbh & Co. Kg	Pyrazolopyrimidines as therapeutic agents
US7217722B2 (en) *	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
RU2240826C2 (ru) *	2000-02-03	2004-11-27	Эйсай Ко., Лтд.	Ингибитор экспрессии интегрина
AU2001280187A1 (en) *	2000-08-28	2002-03-13	Toray Industries, Inc.	Cyclic amine derivatives
KR20090090406A (ko) *	2000-12-18	2009-08-25	가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼	염증성 사이토카인 생산 유리 억제제
US6982274B2 (en) *	2001-04-16	2006-01-03	Eisai Co., Ltd.	1H-indazole compound
WO2002100833A1 (en) *	2001-06-12	2002-12-19	Sumitomo Pharmaceuticals Company, Limited	Rho KINASE INHIBITORS
ITMI20012060A1 (it) *	2001-10-05	2003-04-05	Recordati Chem Pharm	Nuovi eterocilcli n-acilati
TW200306819A (en) *	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
DE10228103A1 (de)	2002-06-24	2004-01-15	Bayer Cropscience Ag	Fungizide Wirkstoffkombinationen
WO2004009557A1 (en) *	2002-07-19	2004-01-29	Memory Pharmaceuticals Corporation	6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
RS51752B (sr) *	2002-07-29	2011-12-31	Rigel Pharmaceuticals	Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US20040110802A1 (en)	2002-08-23	2004-06-10	Atli Thorarensen	Antibacterial benzoic acid derivatives
CA2499128C (en) *	2002-09-25	2012-07-31	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
MXPA05007857A (es)	2003-01-22	2005-10-18	Lilly Co Eli	Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
US7563748B2 (en) *	2003-06-23	2009-07-21	Cognis Ip Management Gmbh	Alcohol alkoxylate carriers for pesticide active ingredients
JP4110324B2 (ja) *	2003-10-15	2008-07-02	宇部興産株式会社	新規インダゾール誘導体
WO2005092854A1 (en) *	2004-03-03	2005-10-06	Eli Lilly And Company	Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
EP1769092A4 (en)	2004-06-29	2008-08-06	Europ Nickel Plc	IMPROVED LIXIVIATION OF BASE METALS
EP1632491A1 (en) *	2004-08-30	2006-03-08	Laboratorios Del Dr. Esteve, S.A.	Substituted indole compounds and their use as 5-HT6 receptor modulators
WO2006058338A2 (en) *	2004-11-29	2006-06-01	Janssen Pharmaceutica N.V.	4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
WO2006062982A2 (en) *	2004-12-07	2006-06-15	Locus Pharmaceuticals, Inc.	Urea inhibitors of map kinases
WO2006112549A1 (ja) *	2005-04-20	2006-10-26	Takeda Pharmaceutical Company Limited	縮合複素環化合物
WO2007076161A2 (en) *	2005-12-27	2007-07-05	Myriad Genetics, Inc	Compounds with therapeutic activity
TW200736232A (en) *	2006-01-26	2007-10-01	Astrazeneca Ab	Pyrimidine derivatives
WO2008050821A1 (en) *	2006-10-19	2008-05-02	Takeda Pharmaceutical Company Limited	Indole compound
SI2178870T1 (sl) *	2007-08-17	2018-11-30	Lg Chem, Ltd.	Indolne in indazolne spojine kot inhibitor celične nekroze
EP2220081A4 (en) *	2007-12-20	2011-08-24	Lg Life Sciences Ltd	GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES
RU2460525C2 (ru) *	2008-01-04	2012-09-10	Эл Джи Лайф Сайенсиз Лтд.	Производные индола и индазола, обладающие консервирующим действием по отношению к клеткам, тканям и органам

2008
- 2008-08-18 SI SI200831995T patent/SI2178870T1/sl unknown
- 2008-08-18 BR BRPI0814958A patent/BRPI0814958B8/pt active IP Right Grant
- 2008-08-18 CN CN2008801030261A patent/CN101784543B/zh active Active
- 2008-08-18 ES ES08793298.4T patent/ES2691068T3/es active Active
- 2008-08-18 CN CN200880103002.6A patent/CN101801965B/zh active Active
- 2008-08-18 US US12/671,180 patent/US8222414B2/en active Active
- 2008-08-18 DK DK08793298.4T patent/DK2178870T3/en active
- 2008-08-18 KR KR1020080080519A patent/KR20090018593A/ko not_active Ceased
- 2008-08-18 RU RU2010109895/04A patent/RU2477282C2/ru active
- 2008-08-18 RU RU2010109898/04A patent/RU2437883C1/ru active
- 2008-08-18 EP EP08793298.4A patent/EP2178870B1/en active Active
- 2008-08-18 WO PCT/KR2008/004784 patent/WO2009025478A1/en not_active Ceased
- 2008-08-18 US US12/671,038 patent/US8436038B2/en active Active
- 2008-08-18 PT PT08793298T patent/PT2178870T/pt unknown
- 2008-08-18 BR BRPI0815154-7A patent/BRPI0815154B1/pt active IP Right Grant
- 2008-08-18 MX MX2010000985A patent/MX368368B/es active IP Right Grant
- 2008-08-18 KR KR1020080080537A patent/KR101098584B1/ko active Active
- 2008-08-18 EP EP08793297.6A patent/EP2178869B1/en active Active
- 2008-08-18 JP JP2010521775A patent/JP5517935B2/ja active Active
- 2008-08-18 ES ES08793297T patent/ES2426641T3/es active Active
- 2008-08-18 JP JP2010521774A patent/JP5323834B2/ja active Active
- 2008-08-18 WO PCT/KR2008/004783 patent/WO2009025477A1/en not_active Ceased
2012
- 2012-06-11 US US13/493,045 patent/US8569307B2/en active Active
2013
- 2013-04-09 US US13/859,581 patent/US9000028B2/en active Active
- 2013-09-23 US US14/034,234 patent/US8889691B2/en active Active

Also Published As

Publication number	Publication date
US8222414B2 (en)	2012-07-17
CN101784543B (zh)	2013-10-16
KR101098584B1 (ko)	2011-12-26
ES2691068T3 (es)	2018-11-23
US9000028B2 (en)	2015-04-07
JP5517935B2 (ja)	2014-06-11
US20100210647A1 (en)	2010-08-19
EP2178869A1 (en)	2010-04-28
RU2010109895A (ru)	2011-09-27
JP5323834B2 (ja)	2013-10-23
BRPI0814958B8 (pt)	2021-05-25
EP2178870A4 (en)	2012-04-11
EP2178870A1 (en)	2010-04-28
BRPI0815154B1 (pt)	2024-01-30
KR20090018593A (ko)	2009-02-20
US8569307B2 (en)	2013-10-29
CN101801965A (zh)	2010-08-11
DK2178870T3 (en)	2018-10-22
US8889691B2 (en)	2014-11-18
MX368368B (es)	2019-09-30
JP2010536845A (ja)	2010-12-02
PT2178870T (pt)	2018-11-09
KR20090018594A (ko)	2009-02-20
WO2009025478A1 (en)	2009-02-26
US20130237532A1 (en)	2013-09-12
ES2426641T3 (es)	2013-10-24
BRPI0814958A2 (pt)	2015-02-03
EP2178870B1 (en)	2018-09-19
JP2010536846A (ja)	2010-12-02
US20120252798A1 (en)	2012-10-04
SI2178870T1 (sl)	2018-11-30
EP2178869B1 (en)	2013-06-12
BRPI0814958B1 (pt)	2021-05-11
WO2009025477A1 (en)	2009-02-26
US20140024618A1 (en)	2014-01-23
US20100197673A1 (en)	2010-08-05
US8436038B2 (en)	2013-05-07
EP2178869A4 (en)	2012-03-21
CN101801965B (zh)	2014-07-30
RU2477282C2 (ru)	2013-03-10
RU2437883C1 (ru)	2011-12-27
CN101784543A (zh)	2010-07-21
RU2010109898A (ru)	2011-09-27

Publication	Publication Date	Title
BRPI0815154A2 (pt)	2015-03-31	Compostos de indol, composição para a prevenção ou tratamento de necrose e doenças associadas com a necrose, e, método de preparação da mesma
PT1830843E (pt)	2013-02-06	Derivados de indolinona para o tratamento ou prevenção de doenças fibróticas
BRPI0906634A2 (pt)	2015-07-14	Drivados de indol 2-carboxamidas e de azaindol 2-carboxamidas substituídos por grupo sinanila, sua preparação e sua aplicação em terapêutica
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0816116A2 (pt)	2015-03-03	Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0917138A2 (pt)	2015-11-17	composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0816784A2 (pt)	2015-03-24	Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0816175A2 (pt)	2015-02-24	Composições adequadas para tratamento de doença, distúrbio ou condição da espinha.
CL2007002972A1 (es)	2008-05-30	Compuestos derivados de imidazolona e imidazolidinona, inhibidores de la 11b-hsd1; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para el tratamiento y prevencion de diabetes, obesidad, trastornos alimentarios, disl
BRPI0820632A2 (pt)	2015-06-16	Compostos de indol e métodos para tratamento de dor visceral
BRPI0912348A2 (pt)	2015-10-13	composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
EA200900798A1 (ru)	2010-10-29	Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
BRPI0812524A2 (pt)	2014-10-21	Amidohidrolases para a preparação de gêneros alimentícios ou estimulantes
BRPI0812755A2 (pt)	2014-09-30	Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
BRPI0911203A2 (pt)	2016-07-05	peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
CL2007002919A1 (es)	2008-03-14	Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.
WO2009071689A3 (de)	2009-07-23	5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CL2007003832A1 (es)	2008-07-25	Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
BRPI0911577A8 (pt)	2018-03-06	derivados espiro-indol para o tratamento de doenças parasíticas.
HUE050319T2 (hu)	2020-11-30	Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére
BRPI0821450A2 (pt)	2015-06-16	Derivado (aza) indol substituído na posição 5, proceso para a preparação do mesmo, composto intermediário, e, composição farmacêutica.
IL204886B (en)	2018-02-28	A pharmaceutical preparation for the treatment of disorders of the stomach and intestines independent of food consumption

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-08	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-09-18	B25G	Requested change of headquarter approved	Owner name: LG LIFE SCIENCES LTD. (KR)
2018-10-02	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2018-10-09	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2491 DE 02/10/2018 POR TER SIDO INDEVIDA.
2018-10-09	B25G	Requested change of headquarter approved	Owner name: LG LIFE SCIENCES LTD. (KR)
2018-10-30	B25A	Requested transfer of rights approved	Owner name: LG CHEM, LTD (KR)
2019-01-29	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-06-04	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-10-22	B09B	Patent application refused [chapter 9.2 patent gazette]
2019-12-31	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2024-01-30	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2024-03-26	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REF. RPI 2769 DE 30/01/2024 QUANTO AO TITULO.